We have a solution for everything – and the corresponding experience. In our current seven areas of expertise, we are at your disposal with our comprehensive know-how.

All Solutions

Software solutions

Software solutions

With our Werum PAS-X MES - on premise or cloud-based - and our software solutions for analysis, track & trace, networked factories, and intelligent packaging, we are the world's leading supplier and partner to the pharmaceutical and biotech industries.

Overview Software solutions

Handling systems

Handling systems

We are specialists for complete handling systems for pharmaceutical and medical products. Our solutions are decisive in the field of contactless and safe transport of e.g. glass syringes.

Overview Handling systems

Inspection machines


As the world's leading inspection expert, we develop solutions for the pharmaceutical and biotech industries. Our range of products extends from high-performance machines and semi-automatic machines to laboratory units and inspection applications for in-process control.

Overview Inspection

Machine finder

Packaging machines

Packaging machines

We are a leading supplier of packaging machines for liquid and solid pharmaceutical and medical products. With our blister, sachet and stick packaging machines we offer solutions for primary packaging. Our side and topload cartoners set standards worldwide for secondary packaging.

Overview Packaging machines

K.Pak Topload Case Packer

Introducing our latest solution from Körber; the K.Pak Topload Case Packer! Created specifically for the pharmaceutical industry, the K.Pak solution provides operator-friendly machines to complete any production line. Our solution focuses on innovative technology, high-quality design and expert handling and packaging of your product. It’s time to start connecting the dots with Körber!

Packaging solutions

Packaging solutions

As long-standing specialists, we develop packaging solutions for innovative and high-quality secondary pharmaceutical packaging made of cardboard. We offer you solutions for counterfeit protection, standard folding boxes and much more.

Overview Packaging solutions



Our experts will advise you during the analysis of your requirements, show you optimisation potential and support you during the implementation of projects in all areas of the pharmaceutical, biotech and medical device industry.

Overview Consulting

Lukas Marschall


What is a (qualified) bioprocess scale down model?


  • What is a bioprocess scale down model;
  • Regulatory guidance about scale down models;
  • Pitfalls in developing scale-down models;
  • Best practices to qualify scale-down models.

You develop, optimize and characterize bioprocesses in laboratory scale. Yet, you expect that the insights from laboratory scale do not change during scale-up. Hence, your laboratory results are representative and predictive for the final manufacturing scale. To ensure that, you need a robust and predictive bioprocess scale-down model. Therefore, developing the bioprocess scale-down model is the core of your development and validation activities.

What is a bioprocess scale-down model? 

ICH and FDA process validation guidelines provide definitions for bioprocess scale-down models.  ICH Q11 states that a scale-down model is a representation of the commercial process. You have to justify the predictive power of your scale down model:

If you want to learn how to perform a successful process characterization study and what steps need to be taken, visit this blog post. 

„A scale-down model is a representation of the proposed commercial process“ ICH Q11, Step 4
“Small-scale models can be developed and used to support process development studies. The development of a model should account for scale effects and be representative of the proposed commercial process. A scientifically justified model can enable a prediction of quality, and can be used to support the extrapolation of operating conditions across multiple scales and equipment.” ICH Q11 Step 4
 “It is important to understand the degree to which models represent the commercial process, including any differences that might exist, as this may have an impact on the relevance of information derived from the models.” FDA 2011 Process Validation Guideline

Available guidance points out:

  • You need to understand the differences between your scale-down model and the commercial process.
  • You have to make proper use of the knowledge gained from scale-down models. 

Authorities point out the importance of scale-down models. However, authorities provide no specific information on how to develop “compliant” scale-down models.

Why is a “predictive” bioprocess scale-down model so important? 

A non-predictive bioprocess scale down model has severe consequences:

  • The management cost of goods sold (COGs) estimations is incorrect. 
  • Your bioprocess in manufacturing scale runs will run at suboptimal conditions. 
  • Your drug product quality attributes might change during scale-up. Hence, for a biosimilar process, you might lose your product bioequivalence during scale-up.
  • Regulatory bodies review the scale-down model for process validation stage 1. As a result, your validation campaign is at risk.

What can go wrong in designing a bioprocess scale-down model?

But how to justify that your scale-down model is predictive? To do that, you have to understand what can go wrong. In process optimization and process characterization studies, you investigate the influence of potential critical process parameters (pCPPs) on your product quality (critical quality attributes, CQAs). You expect the same effects in small and large scales. However, this might not be the case due to scale-up effects. Figure 1 shows what can go wrong.

Figure 1, plot A: A perfect predictability of your scale-down model means that the same effect that you observe on a small scale (blue trend) exists on a large scale (red trend).; Figure 1, plot B: At target process conditions, you observe an offset between your scale-down model and your commercial process. However, your effects still point in the same direction. Figure 1, plot C: At target process conditions, you observe no offset. However, your effects are different on a large and small scale. Hence, your scale-down model is non-predictive.; Figure 1, plot D: At target process conditions, you observe an offset, and your effects are different on a large and small scale. Hence, your scale-down model is non-predictive.

As a bioprocess scientist dealing with scale-down models, you have to find out for each critical quality attribute (CQA) whether your scale-down model is case A (predictive), B (semi-predictive), or C and D (not predictive). 

Case A is desired as your scale-down model behaves similar to the manufacturing scale process. Therefore, your knowledge gained on a small scale is directly transferable to the manufacturing scale. For case B, an offset in a certain quality attribute can still be accepted if the functional behavior of this quality attribute stays similar across scales. Case C and case D are undesirable.

As manufacturing scale experiments are expensive, a commonly agreed-upon methodology for scale-down model qualification is to qualify the model on set-point conditions. With this approach, you rule out case B and case D. However, if you prove similarity on target, you still do not know whether your effects are similar (case A) or different (case C) across scales. So, case C represents the worst-case scenario, as common statistical methods cannot rule it out. Looking at it theoretically, it is less improbable that different effects (straight lines with different slopes) intersect at target (case C) than they intersect anywhere else (case D). Therefore, different effects (case B) are less likely than similar effects (case A) at similar target behavior. However, to gain absolute assurance, you need to perform large-scale experiments on other than target conditions.

Though, as discussed above, case B might still be acceptable, but regarding the patients' risk, it is better to reject similarity of your scale-down model rather too much than too little.

Best practices to establish bioprocess scale-down models

Best practices for qualification scale-down models are based on the combination of statistical tools (equivalence testing), multivariate data analysis, and risk assessments. Here are the main messages:

  • Explore multivariate differences between small and commercial scales by multivariate data analysis.
  • Use equivalence testing & time series equivalence testing to demonstrate the quality of your scale-down model. 
  • Use a risk-based approach and simulations to deal with the risk of offsets.
  • Implement the results to assess the overall criticality of the process parameters.
[Translate to English:] Figure 2: Illustration of the best-practice workflow for scale-down model qualification.

Software to support scale-down model development

Werum PAS-X Savvy is a bioprocess data management and data analytics software. Leading biotech companies use Werum PAS-X Savvy for bioprocess development, characterization, and scale-down model development and qualification. 


No comments

Write comment

* These fields are required

Back to top
Back to top